Briquilimab

Jasper Therapeutics announced the first patient dosed in its Phase 1b/2a ETESIAN study evaluating briquilimab for allergic asthma, aiming to demonstrate proof-of-concept and inform future trials.

Jasper Therapeutics to participate in Stifel 2024 Healthcare Conference, Jefferies London Healthcare Conference 2024, and 7th Annual Evercore ISI HealthCONx Conference. Presentations on briquilimab, targeting c-Kit for mast cell diseases like CSU, CIndU, and asthma.

20+ companies, including Regeneron and Sanofi, are advancing 25+ urticaria drugs through clinical trials, addressing unmet needs in treatment.

Jasper Therapeutics (JSPR) is a clinical-stage biotech focusing on safer conditioning agents and stem cell engineering for hematopoietic stem cell transplants and gene therapies. Their lead compound, JSP191, aims to reduce risks in current conditioning regimens. Recent developments include promising results for Briquilimab in preventing allergic conditions and the announcement of fiscal quarter and year-end results. The company supports its research through strategic partnerships and an inducement equity incentive plan.